View Item 

Show simple item record

Site‐specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis
dc.contributor.authorMisawa, Kiyoshi
dc.contributor.authorMochizuki, Daiki
dc.contributor.authorEndo, Shiori
dc.contributor.authorMima, Masato
dc.contributor.authorMisawa, Yuki
dc.contributor.authorImai, Atsushi
dc.contributor.authorShinmura, Kazuya
dc.contributor.authorKanazawa, Takeharu
dc.contributor.authorCarey, Thomas E.
dc.contributor.authorMineta, Hiroyuki
dc.date.accessioned2017-04-13T20:34:06Z
dc.date.available2018-05-15T21:02:50Zen
dc.date.issued2017-03
dc.identifier.citationMisawa, Kiyoshi; Mochizuki, Daiki; Endo, Shiori; Mima, Masato; Misawa, Yuki; Imai, Atsushi; Shinmura, Kazuya; Kanazawa, Takeharu; Carey, Thomas E.; Mineta, Hiroyuki (2017). "Site‐specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis." Molecular Carcinogenesis 56(3): 1107-1116.
dc.identifier.issn0899-1987
dc.identifier.issn1098-2744
dc.identifier.urihttps://hdl.handle.net/2027.42/136246
dc.publisherWiley Periodicals, Inc.
dc.publisherCambridge University Press
dc.subject.othergalanin
dc.subject.otherGALR1/2
dc.subject.otherhypermethylation
dc.subject.otheroral and oropharyngeal cancer
dc.subject.otherHPV
dc.titleSite‐specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136246/1/mc22577.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136246/2/mc22577_am.pdf
dc.identifier.doi10.1002/mc.22577
dc.identifier.sourceMolecular Carcinogenesis
dc.identifier.citedreferenceChung W, Kwabi‐Addo B, Ittmann M, et al. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS ONE 2008; 3: e2079.
dc.identifier.citedreferenceLleras RA, Smith RV, Adrien LR, et al. Unique DNA methylation loci distinguish anatomic site and HPV status in head and neck squamous cell carcinoma. Clin Cancer Res 2013; 19: 5444 – 5455.
dc.identifier.citedreferenceChoudhury JH, Ghosh SK. Promoter hypermethylation profiling identifies subtypes of head and neck cancer with distinct viral, environmental, genetic and survival characteristics. PLoS ONE 2015; 10: e0129808.
dc.identifier.citedreferenceOvchinnikov DA, Cooper MA, Pandit P, et al. Tumor‐suppressor gene promoter hypermethylation in saliva of head and neck cancer patients. Transl Oncol 2012; 5: 321 – 326.
dc.identifier.citedreferenceSmith IM, Mydlarz WK, Mithani SK, Califano JA. DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer 2007; 121: 1724 – 1728.
dc.identifier.citedreferenceMisawa K, Ueda Y, Kanazawa T, et al. Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res 2008; 14: 7604 – 7613.
dc.identifier.citedreferenceMisawa Y, Misawa K, Kanazawa T, et al. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer. Cancer 2014; 120: 205 – 213.
dc.identifier.citedreferenceLappano R, Maggiolini M. G protein‐coupled receptors: Novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011; 10: 47 – 60.
dc.identifier.citedreferenceKanazawa T, Misawa K, Carey TE. Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma. Expert Opin Ther Targets 2010; 14: 289 – 302.
dc.identifier.citedreferenceSmith EM, Rubenstein LM, Haugen TH, Pawlita M, Turek LP. Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: A case for multifactor disease. J Oncol 2012; 2012: 571862.
dc.identifier.citedreferenceSmith EM, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP. Tobacco and alcohol use increases the risk of both HPV‐associated and HPV‐independent head and neck cancers. Cancer Causes Control 2010; 21: 1369 – 1378.
dc.identifier.citedreferenceSartor MA, Dolinoy DC, Jones TR, et al. Genome‐wide methylation and expression differences in HPV(+) and HPV(−) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 2011; 6: 777 – 787.
dc.identifier.citedreferenceKaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein‐Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res 2012; 72: 3445 – 3450.
dc.identifier.citedreferenceBar‐Shavit R, Maoz M, Kancharla A, et al. G protein‐coupled receptors in cancer. Int J Mol Sci 2016; 17: E1320.
dc.identifier.citedreferenceMisawa K, Kanazawa T, Misawa Y, et al. Frequent promoter hypermethylation of tachykinin‐1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer. J Cancer Res Clin Oncol 2013; 139: 879 – 889.
dc.identifier.citedreferenceJin Z, Olaru A, Yang J, et al. Hypermethylation of tachykinin‐1 is a potential biomarker in human esophageal cancer. Clin Cancer Res 2007; 13: 6293 – 6300.
dc.identifier.citedreferenceMori Y, Cai K, Cheng Y, et al. A genome‐wide search identifies epigenetic silencing of somatostatin, tachykinin‐1, and 5 other genes in colon cancer. Gastroenterology 2006; 131: 797 – 808.
dc.identifier.citedreferenceFreimann K, Kurrikoff K, Langel U. Galanin receptors as a potential target for neurological disease. Expert Opin Ther Targets 2015; 19: 1665 – 1676.
dc.identifier.citedreferenceDoufekas K, Hadwin R, Kandimalla R, et al. GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer. Int J Gynecol Cancer 2013; 23: 1050 – 1055.
dc.identifier.citedreferenceKim JC, Lee HC, Cho DH, et al. Genome‐wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers. J Cancer Res Clin Oncol 2011; 137: 1571 – 1580.
dc.identifier.citedreferenceYu J, Zhang HY, Ma ZZ, Lu W, Wang YF, Zhu JD. Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 2003; 13: 319 – 333.
dc.identifier.citedreferenceStevenson L, Allen WL, Turkington R, et al. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. Clin Cancer Res 2012; 18: 5412 – 5426.
dc.identifier.citedreferenceKim KY, Kee MK, Chong SA, Nam MJ. Galanin is up‐regulated in colon adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2007; 16: 2373 – 2378.
dc.identifier.citedreferenceBerger A, Lang R, Moritz K, et al. Galanin receptor subtype GalR2 mediates apoptosis in SH‐SY5Y neuroblastoma cells. Endocrinology 2004; 145: 500 – 507.
dc.identifier.citedreferenceKanazawa T, Iwashita T, Kommareddi P, et al. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: Activation of the extracellular signal regulated kinase pathway and induction of cyclin‐dependent kinase inhibitors. Oncogene 2007; 26: 5762 – 5771.
dc.identifier.citedreferenceKanazawa T, Kommareddi PK, Iwashita T, et al. Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells. Clin Cancer Res 2009; 15: 2222 – 2230.
dc.identifier.citedreferenceKanazawa T, Misawa K, Misawa Y, et al. G‐protein‐coupled receptors: Next generation therapeutic targets in head and neck cancer ? Toxins (Basel) 2015; 7: 2959 – 2984.
dc.identifier.citedreferenceMisawa K, Misawa Y, Kanazawa T, et al. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer. Clin Exp Metastasis 2016; 33: 187 – 195.
dc.identifier.citedreferenceJurkowski W, Yazdi S, Elofsson A. Ligand binding properties of human galanin receptors. Mol Membr Biol 2013; 30: 206 – 216.
dc.identifier.citedreferenceKatz MH. Multivariable analysis: A practical guide for clinicians and public health researchers. Cambridge: Cambridge University Press; 2011. pp. 93 – 117.
dc.identifier.citedreferenceArantes LM, de Carvalho AC, Melendez ME, Carvalho AL, Goloni‐Bertollo EM. Methylation as a biomarker for head and neck cancer. Oral Oncol 2014; 50: 587 – 592.
dc.identifier.citedreferenceSepiashvili L, Bruce JP, Huang SH, O’Sullivan B, Liu FF, Kislinger T. Novel insights into head and neck cancer using next‐generation “omic” technologies. Cancer Res 2015; 75: 480 – 486.
dc.identifier.citedreferenceKang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol 2015; 12: 11 – 26.
dc.identifier.citedreferenceParkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74 – 108.
dc.identifier.citedreferenceWhang SN, Filippova M, Duerksen‐Hughes P. Recent progress in therapeutic treatments and screening strategies for the prevention and treatment of HPV‐associated head and neck cancer. Viruses 2015; 7: 5040 – 5065.
dc.identifier.citedreferenceDayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta‐analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010; 2: 15.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
mc22577.pdf
Size:
560.4KB
Format:
PDF
View/Open
Name:
mc22577_am.pdf
Size:
139.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.